---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-087352"
form_type: "8-K"
ticker: null
cik: "0001697532"
company_name: "Applied Therapeutics, Inc."
filed_at: "2025-06-17T23:59:59+00:00"
generated_at: "2026-05-19T04:43:02.954062+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Applied Therapeutics reports mixed govorestat Phase 2/3 results; CMO departs, Bailey named

## Summary
- INSPIRE trial primary endpoint 10MWRT not met (p=0.7287); stat sig correlation between sorbitol reduction and CMT-HI (p<0.001) and lower limb domain (p=0.038).
- Key secondary endpoint CMT-HI showed stat sig improvement at 12 months; sorbitol reduction maintained through 24 months; MRIs suggest slowing of disease progression.
- CMO Riccardo Perfetti departed June 15; Evan Bailey appointed CMO. Bailey gets $585k base salary, 300k RSUs vesting over 4 years.
- Govorestat generally safe and well tolerated through 24 months; similar adverse event rates between active and placebo groups.

## SEC filing metadata
- accession: 0000950170-25-087352
- form_type: 8-K
- cik: 0001697532
- company_name: Applied Therapeutics, Inc.
- filed_at: 2025-06-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1697532/000095017025087352/0000950170-25-087352-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1697532/000095017025087352/aplt-20250615.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-087352
- JSON: https://secwatch.observer/filing/0000950170-25-087352.json
- Plain text: https://secwatch.observer/filing/0000950170-25-087352.txt

## Key facts
- Executive change
  Riccardo Perfetti departed as Chief Medical Officer at Applied Therapeutics, Inc..
  - Action: departed
  - Role: Chief Medical Officer
  source text: Riccardo Perfetti, M.D., Ph.D., departed his role as Chief Medical Officer, effective as of June 15, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1697532/000095017025087352/0000950170-25-087352-index.htm
- Executive change
  Evan P. Bailey was appointed as Chief Medical Officer at Applied Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Medical Officer
  source text: Effective as of June 15, 2025, the Board appointed Evan P. Bailey, the Company’s Senior Vice President, Clinical Development, to succeed Dr. Perfetti as Chief Medical Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1697532/000095017025087352/0000950170-25-087352-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.